Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy October 7, 2026 4:00 PM EDT
Company Participants
Linda Marbán – Co-Founder, President, CEO & Director
Craig McDonald
Nathaniel Hogan
Presentation
Unknown Executive
All right. It looks like a good number of folks are connected online. So we’re going to get started. So welcome, everyone. Thank you for joining us today for this webinar with Capricor Therapeutics, where they’re going to be providing an overview of some of the new HOPE-3, 2-year open-label extension data and then having an update ahead of the November PDUFA date. Just some general housekeeping. This meeting or webinar is being recorded. So if you have to step away, if you have someone that this would be irrelevant to, the recording should be up on the website in about a week’s time.
And then at the end of today, we will have an open Q&A. So during the presentation, if you have questions, there’s a Q&A box at the bottom of your screen. Please submit questions there. We will try to get through those and the ones that were submitted ahead of time as we can. So we’re joined by a few members of the Capricor team as well as Dr. Craig McDonald and Dr. Chet Villa today. So we’ll hopefully be able to answer all of your questions. And I think with that, I’m going to hand it over to Linda Marbán to get us started.
Linda Marbán
Co-Founder, President, CEO & Director
Good morning or good afternoon, depending upon where you are. I want to thank you for joining today’s call. I also want to thank PPMD for making this presentation possible and look forward to your questions at the end. Today, we will present an update on deramiocel for the treatment of
